GPC-3 Antibodies for ADCC-Mediated HCC Cell Killing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Hepatocellular carcinoma (HCC) is challenging to treat due to its late-stage diagnosis in most patients, and existing therapies like Sorafenib offer limited clinical benefits with low response rates, necessitating the development of novel treatment strategies.
Innovation Solution
Development of antibodies or antigen-binding fragments specifically targeting glypican-3 (GPC-3) with high affinity and ability to induce Antibody-Dependent Cell-mediated Cytotoxicity (ADCC), combined with chimeric antigen receptors (CAR) for enhanced tumor cell killing, and potential use in antibody-drug conjugates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Sorafenib is used as targeted therapy for HCC, then patients receive a approved treatment option, but the response rate remains low and overall survival improvement is limited
Solution Approach 1:
The patent changes the therapeutic parameter from small molecule kinase inhibition (Sorafenib) to antibody-based targeted therapy against GPC-3, a surface antigen specifically overexpressed in HCC. This parameter change enables higher response rates and improved overall survival by targeting a different molecular pathway and utilizing antibody-dependent cellular cytotoxicity mechanisms
Solution Approach 2:
The patent introduces GPC-3 antibodies as an intermediary substance that specifically binds to glypican-3 on HCC cells, recruiting immune cells to mediate tumor cell destruction. This intermediary approach overcomes the limitations of direct kinase inhibition by Sorafenib and enables more effective tumor cell killing through immune-mediated mechanisms
2Reliability
If novel treatment strategies are developed for HCC, then treatment efficacy may be improved, but the development process becomes more challenging and time-consuming
Solution Approach 1:
The patent develops GPC-3 antibodies with multiple functions: direct tumor cell binding, induction of antibody-dependent cellular cytotoxicity (ADCC), and potential for conjugation with cytotoxic agents. This multi-functionality allows a single therapeutic modality to address multiple aspects of HCC treatment, simplifying the overall development approach while maintaining high efficacy
Solution Approach 2:
The patent identifies and validates GPC-3 as a tumor-specific target before developing the antibody therapy. By establishing GPC-3 overexpression in HCC and its absence in normal tissues as a preliminary finding, the development pathway is streamlined, enabling faster progression to clinical trials compared to de novo target discovery
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies and CAR T cells effectively target and kill HCC cells, offering a promising therapeutic approach with potential for improved treatment outcomes.
Implementation Method 1
The antibody or antigen-binding fragment may be capable of specifically binding to glypican-3 (GPC-3)
Implementation Method 2
The antibody or antigen-binding fragment may be capable of inducing Antibody-Dependent Cell-mediated Cytotoxicity (ADCC) of a GPC-3 expressing cell
Data Source
AI summary
We describe an antibody or antigen-binding fragment thereof comprising a heavy chain variable region (VH) sequence and a light chain variable region (VL) sequence of a clone selected from: 5C4, 4H1, 1D2, 1C4, 2B5, 1F1, 1H1, 4A5, 1D8, 1D3, 2F1, 3C6, 3D12, 3A9, 1F4, 1H10, 3C12, 4G11, 4A12, 1A12, 3G12, 4F9, 4G4 and 1E1 which is capable of specifically binding to glypican-3 (GPC-3) (GenBank Accession Number: NP_004475.1), or a sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity thereto.